Choi Ae-Ran, Kim Ju-Hwa, Cheon Ji Hyun, Kim Hyung Sik, Yoon Sungpil
Research Institute, National Cancer Center, Goyang-si, Republic of Korea.
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
Anticancer Res. 2016 Nov;36(11):5859-5866. doi: 10.21873/anticanres.11171.
BACKGROUND/AIM: Colchicine (COL) is a well-known and potent microtubule targeting anticancer agent. The purpose of our study was to identify conditions that increase sensitization of COL-resistant cancer cells that overexpress P-glycoprotein (P-gp).
The anti-malarial drugs chloroquine (CHL), mefloquine (MEF) and primaquine (PRI) have been shown to increase sensitization in drug-resistant KBV20C cells via P-gp inhibition. Therefore, we tested whether co-treatment of COL with PRI, CHL or MEF increases sensitivity in COL-resistant KBV20C cells over that of cells treated with COL alone and whether these effects are attributable to P-gp activity.
Interestingly, we found that both CHL and PRI, but not MEF, reduced cytotoxicity in KBV20C cells receiving high concentrations of COL, suggesting that the effects of CHL and PRI have specific mechanisms among the anti-malarial drugs. The effects of CHL and PRI were specific to COL-resistant cells, since we did not detect a reduction in cytotoxicity in drug-sensitive parent KB cells. These data suggest that CHL and PRI inhibit the signaling pathways of COL-treated-resistant cells without P-gp inhibition. Furthermore, we studied the molecular mechanisms underlying the effects of COL-CHL co-treatment in KBV20C cells. FACS analysis, annexin V staining and western blot analysis revealed that G arrest and apoptosis were lower in cells co-treated with COL and CHL than in cells treated with COL alone. We also found that pH2AX, pHistone H3 and pRb expression was highly reduced in COL-CHL co-treated cells but not in COL-VIB co-treated cells. In addition, expression of the p21 protein, which correlates with drug-resistant phenotypes, increased in cells receiving COL-CHL co-treatment over that of COL-treated cells.
These results suggest that reduced G arrest and apoptosis resulting from COL-CHL co-treatment was attributable to DNA damage and reduced cell cycle progression. These findings provide important information regarding the prevention of COL toxicity in COL-resistant cells and indicate that CHL, PRI and MEF may contribute to sensitization in COL-resistant cells.
背景/目的:秋水仙碱(COL)是一种知名的强效微管靶向抗癌药物。我们研究的目的是确定能增强对过表达P-糖蛋白(P-gp)的COL耐药癌细胞敏感性的条件。
抗疟药物氯喹(CHL)、甲氟喹(MEF)和伯氨喹(PRI)已被证明可通过抑制P-gp增加耐药KBV20C细胞的敏感性。因此,我们测试了COL与PRI、CHL或MEF联合处理是否比单独用COL处理的细胞更能提高COL耐药KBV20C细胞的敏感性,以及这些作用是否归因于P-gp活性。
有趣的是,我们发现CHL和PRI,但不是MEF,降低了接受高浓度COL的KBV20C细胞的细胞毒性,这表明CHL和PRI在抗疟药物中有特定的作用机制。CHL和PRI的作用对COL耐药细胞具有特异性,因为我们在药物敏感的亲本KB细胞中未检测到细胞毒性的降低。这些数据表明,CHL和PRI在不抑制P-gp的情况下抑制了COL处理的耐药细胞的信号通路。此外,我们研究了COL-CHL联合处理在KBV20C细胞中作用的分子机制。流式细胞术分析、膜联蛋白V染色和蛋白质印迹分析显示,与单独用COL处理的细胞相比,COL和CHL联合处理的细胞中G期阻滞和凋亡较低。我们还发现,COL-CHL联合处理的细胞中pH2AX、磷酸化组蛋白H3和磷酸化Rb的表达显著降低,而COL-VIB联合处理的细胞中未降低。此外,与耐药表型相关的p21蛋白的表达在接受COL-CHL联合处理的细胞中比接受COL处理的细胞中增加。
这些结果表明,COL-CHL联合处理导致的G期阻滞和凋亡减少归因于DNA损伤和细胞周期进程减慢。这些发现为预防COL耐药细胞中的COL毒性提供了重要信息,并表明CHL、PRI和MEF可能有助于提高COL耐药细胞的敏感性。